Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BAFFR-CAR-NK cell therapy
- Development stage
- Preclinical
- Lead developer
- PeproMene Bio
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
BAFFR-CAR-NK cell therapy is an investigational allogeneic (off-the-shelf) cell therapy being developed by PeproMene Bio. The therapy utilizes natural killer (NK) cells engineered with a chimeric antigen receptor (CAR) that specifically targets the B-cell activating factor receptor (BAFFR). BAFFR is a member of the tumor necrosis factor receptor superfamily and is essential for the survival and maturation of B cells, with expression limited almost exclusively to the B-cell lineage. By targeting BAFFR, this therapy aims to eliminate malignant or pathogenic B cells while potentially offering a safer profile and broader accessibility compared to autologous CAR-T therapies, as NK cells do not require HLA matching and carry a lower risk of graft-versus-host disease. It is currently in preclinical development for the treatment of B-cell malignancies and autoimmune disorders.
- Other names
- BAFFR-targeted CAR-NK cell therapyanti-BAFF receptor CAR-NKPeproMene Bio BAFFR-CAR-NK
02
Targets
TNFRSF13C (B-cell Activating Factor Receptor)
Beyond the preview
Go deeper on BAFFR-CAR-NK cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BAFFR-CAR-NK cell therapy.